Median Technologies (DE:4ZG)
FRANKFURT:4ZG
Want to see DE:4ZG full AI Analyst Report?
4ZG Stock Chart & Stats
€3.22
€0.01(0.25%)
At close: 4:00 PM EST
€3.22
€0.01(0.25%)
Day’s Range― - ―
52-Week Range€1.24 - €6.42
Previous CloseN/A
Volume0.00
Average Volume (3M)81.00
Market Cap
€206.94M
Enterprise Value€210.41M
Total Cash (Recent Filing)€18.41M
Total Debt (Recent Filing)€21.76M
Price to Earnings (P/E)―
Beta-0.34
Next Earnings
Oct 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding37,655,190
10 Day Avg. Volume223
30 Day Avg. Volume81
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-4.95
Price to Sales (P/S)7.45
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.49
Revenue Forecast (FY)€26.53M
Bulls Say, Bears Say
Bulls Say
Improving Revenue GrowthSustained revenue acceleration (noted +21.5% in 2025) indicates growing commercial traction for imaging analytics in trials. Over 2-6 months this trend supports larger deal flow and scale benefits, improving prospects for converting R&D momentum into repeatable service revenues.
Clear Product Focus In Imaging AIA focused business model centered on imaging analytics and AI for oncology aligns with durable structural demand from drug developers. Specialization in image-based biomarkers helps create technical differentiation and sticky client workflows that sustain long-term contract opportunities.
Clinical-trial Revenue Streams & PartnershipsDiversified revenue pathways—project-based trial services, platform licenses and collaborations—reduce dependence on a single sales channel. This mix supports recurring and milestone billing patterns that can stabilize cash inflows as trial volumes and biomarker adoption grow over time.
Bears Say
Persistent Cash BurnChronic negative operating cash flow implies the company must rely on external financing to fund operations. Over 2-6 months this reduces strategic flexibility, raises dilution and refinancing risks, and can constrain investment in product development or commercial expansion if capital markets tighten.
Negative Shareholders' EquityA sustained negative equity base weakens the balance sheet and limits the firm’s ability to absorb shocks or secure favorable debt. Structurally this raises counterparty concerns, increases borrowing costs or covenant constraints, and heightens reliance on equity raises that dilute existing holders.
Deep, Persistent Losses And Margin PressureVery large net losses and negative gross profit indicate the current cost structure or pricing/mix is unsustainable. Over months this threatens scalability: until gross margins recover, profitable growth is unlikely and the company may need to restructure offerings or pricing to achieve durable profitability.
Median Technologies News
4ZG FAQ
What was Median Technologies’s price range in the past 12 months?
Median Technologies lowest stock price was €1.24 and its highest was €6.42 in the past 12 months.
What is Median Technologies’s market cap?
Median Technologies’s market cap is €206.94M.
When is Median Technologies’s upcoming earnings report date?
Median Technologies’s upcoming earnings report date is Oct 15, 2026 which is in 147 days.
How were Median Technologies’s earnings last quarter?
Median Technologies released its earnings results on Apr 23, 2026. The company reported -€0.677 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.677.
Is Median Technologies overvalued?
According to Wall Street analysts Median Technologies’s price is currently Overvalued.
Does Median Technologies pay dividends?
Median Technologies does not currently pay dividends.
What is Median Technologies’s EPS estimate?
Median Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Median Technologies have?
Median Technologies has 37,655,190 shares outstanding.
What happened to Median Technologies’s price movement after its last earnings report?
Median Technologies reported an EPS of -€0.677 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.212%.
Which hedge fund is a major shareholder of Median Technologies?
Currently, no hedge funds are holding shares in DE:4ZG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Median Technologies
Median Technologies SA develops and markets software products and platforms for medical image analysis in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iBiops, an end-to-end AI-powered technology software as a medical device that integrates and optimizes the entire medical imaging workflow; and iSee for image analysis services in clinical trials. It also provides imaging contract research services, such as study start up, image and clinical data management, scientific consulting, independent reviews, image data processing and site support, and study close-out for studies. Median Technologies SA has a research collaboration agreement with the University of California. The company was founded in 2002 and is based in Valbonne, France.